Mon, Mar 2, 2015, 12:11 PM EST - U.S. Markets close in 3 hrs 49 mins


% | $
Quotes you view appear here for quick access.

Array BioPharma, Inc. Message Board

  • dcaf7 dcaf7 Apr 12, 2013 5:01 PM Flag

    New phase 1/2 study with MEK162

    Official Title: A Phase I/II Study of First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma

    Purpose: The purpose of this study is to test an investigational combination of drugs for bile duct or gallbladder cancers. Gemcitabine and cisplatin are two forms of chemotherapy commonly used in combination to treat bile duct and gallbladder cancers. The investigators are looking to improve treatment results. They will attempt to do so by adding the drug MEK162 to the treatment plan. MEK162 acts by blocking a protein called MEK 1/2 which helps cancer cells grow and divide. This study will help answer the question of whether MEK162 is a helpful drug in patients with bile duct or gallbladder cancers when given with gemcitabine and cisplatin.

    Sponsor: Memorial Sloan-Kettering Cancer Center

    Collaborator: Novartis Pharmaceuticals

8.4398+0.4798(+6.03%)12:11 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.